Literature DB >> 30728142

Dissecting CLL through high-dimensional single-cell technologies.

Satyen H Gohil1,2, Catherine J Wu1,2,3,4.   

Abstract

We now have the potential to undertake detailed analysis of the inner workings of thousands of cancer cells, one cell at a time, through the emergence of a range of techniques that probe the genome, transcriptome, and proteome combined with the development of bioinformatics pipelines that enable their interpretation. This provides an unprecedented opportunity to better understand the heterogeneity of chronic lymphocytic leukemia and how mutations, activation states, and protein expression at the single-cell level have an impact on disease course, response to treatment, and outcomes. Herein, we review the emerging application of these new techniques to chronic lymphocytic leukemia and examine the insights already attained through this transformative technology.
© 2019 by The American Society of Hematology.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30728142      PMCID: PMC6440295          DOI: 10.1182/blood-2018-09-835389

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   25.476


  114 in total

Review 1.  Mass cytometry: a powerful tool for dissecting the immune landscape.

Authors:  Yannick Simoni; Melissa Hui Yen Chng; Shamin Li; Michael Fehlings; Evan W Newell
Journal:  Curr Opin Immunol       Date:  2018-04-11       Impact factor: 7.486

2.  Pembrolizumab in patients with CLL and Richter transformation or with relapsed CLL.

Authors:  Wei Ding; Betsy R LaPlant; Timothy G Call; Sameer A Parikh; Jose F Leis; Rong He; Tait D Shanafelt; Sutapa Sinha; Jennifer Le-Rademacher; Andrew L Feldman; Thomas M Habermann; Thomas E Witzig; Gregory A Wiseman; Yi Lin; Erik Asmus; Grzegorz S Nowakowski; Michael J Conte; Deborah A Bowen; Casey N Aitken; Daniel L Van Dyke; Patricia T Greipp; Xin Liu; Xiaosheng Wu; Henan Zhang; Charla R Secreto; Shulan Tian; Esteban Braggio; Linda E Wellik; Ivana Micallef; David S Viswanatha; Huihuang Yan; Asher A Chanan-Khan; Neil E Kay; Haidong Dong; Stephen M Ansell
Journal:  Blood       Date:  2017-04-19       Impact factor: 22.113

3.  Hypermorphic mutation of phospholipase C, γ2 acquired in ibrutinib-resistant CLL confers BTK independency upon B-cell receptor activation.

Authors:  Ta-Ming Liu; Jennifer A Woyach; Yiming Zhong; Arletta Lozanski; Gerard Lozanski; Shuai Dong; Ethan Strattan; Amy Lehman; Xiaoli Zhang; Jeffrey A Jones; Joseph Flynn; Leslie A Andritsos; Kami Maddocks; Samantha M Jaglowski; Kristie A Blum; John C Byrd; Jason A Dubovsky; Amy J Johnson
Journal:  Blood       Date:  2015-05-13       Impact factor: 22.113

4.  Transcriptomic Characterization of SF3B1 Mutation Reveals Its Pleiotropic Effects in Chronic Lymphocytic Leukemia.

Authors:  Lili Wang; Angela N Brooks; Jean Fan; Youzhong Wan; Rutendo Gambe; Shuqiang Li; Sarah Hergert; Shanye Yin; Samuel S Freeman; Joshua Z Levin; Lin Fan; Michael Seiler; Silvia Buonamici; Peter G Smith; Kevin F Chau; Carrie L Cibulskis; Wandi Zhang; Laura Z Rassenti; Emanuela M Ghia; Thomas J Kipps; Stacey Fernandes; Donald B Bloch; Dylan Kotliar; Dan A Landau; Sachet A Shukla; Jon C Aster; Robin Reed; David S DeLuca; Jennifer R Brown; Donna Neuberg; Gad Getz; Kenneth J Livak; Matthew M Meyerson; Peter V Kharchenko; Catherine J Wu
Journal:  Cancer Cell       Date:  2016-11-03       Impact factor: 31.743

5.  Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia.

Authors:  Simon F Lacey; Elena J Orlando; Joseph A Fraietta; Iulian Pruteanu-Malinici; Mercy Gohil; Stefan Lundh; Alina C Boesteanu; Yan Wang; Roddy S O'Connor; Wei-Ting Hwang; Edward Pequignot; David E Ambrose; Changfeng Zhang; Nicholas Wilcox; Felipe Bedoya; Corin Dorfmeier; Fang Chen; Lifeng Tian; Harit Parakandi; Minnal Gupta; Regina M Young; F Brad Johnson; Irina Kulikovskaya; Li Liu; Jun Xu; Sadik H Kassim; Megan M Davis; Bruce L Levine; Noelle V Frey; Donald L Siegel; Alexander C Huang; E John Wherry; Hans Bitter; Jennifer L Brogdon; David L Porter; Carl H June; J Joseph Melenhorst
Journal:  Nat Med       Date:  2018-04-30       Impact factor: 53.440

6.  T cells from CLL patients exhibit features of T-cell exhaustion but retain capacity for cytokine production.

Authors:  John C Riches; Jeffrey K Davies; Fabienne McClanahan; Rewas Fatah; Sameena Iqbal; Samir Agrawal; Alan G Ramsay; John G Gribben
Journal:  Blood       Date:  2012-12-17       Impact factor: 22.113

7.  Relation of gene expression phenotype to immunoglobulin mutation genotype in B cell chronic lymphocytic leukemia.

Authors:  A Rosenwald; A A Alizadeh; G Widhopf; R Simon; R E Davis; X Yu; L Yang; O K Pickeral; L Z Rassenti; J Powell; D Botstein; J C Byrd; M R Grever; B D Cheson; N Chiorazzi; W H Wilson; T J Kipps; P O Brown; L M Staudt
Journal:  J Exp Med       Date:  2001-12-03       Impact factor: 14.307

8.  Combining cytogenetic and epigenetic approaches in chronic lymphocytic leukemia improves prognosis prediction for patients with isolated 13q deletion.

Authors:  Cristina Bagacean; Christelle Le Dantec; Christian Berthou; Adrian Tempescul; Hussam Saad; Anne Bordron; Mihnea Zdrenghea; Victor Cristea; Nathalie Douet-Guilbert; Yves Renaudineau
Journal:  Clin Epigenetics       Date:  2017-11-28       Impact factor: 6.551

9.  Regulatory network reconstruction reveals genes with prognostic value for chronic lymphocytic leukemia.

Authors:  Sally Yepes; Maria Mercedes Torres; Liliana López-Kleine
Journal:  BMC Genomics       Date:  2015-11-25       Impact factor: 3.969

Review 10.  Fluorescence In situ Hybridization: Cell-Based Genetic Diagnostic and Research Applications.

Authors:  Chenghua Cui; Wei Shu; Peining Li
Journal:  Front Cell Dev Biol       Date:  2016-09-05
View more
  2 in total

Review 1.  Clonal Evolution of High-Risk Chronic Lymphocytic Leukemia: A Contemporary Perspective.

Authors:  Marwan Kwok; Catherine J Wu
Journal:  Front Oncol       Date:  2021-12-16       Impact factor: 6.244

Review 2.  The mitochondrial anti-apoptotic dependencies of hematologic malignancies: from disease biology to advances in precision medicine.

Authors:  Isacco Ferrarini; Antonella Rigo; Carlo Visco
Journal:  Haematologica       Date:  2022-04-01       Impact factor: 9.941

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.